This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Veltassa
  • /
  • A Two-Part, Single-Blind, Phase 3 Study Evaluating...
Clinical trial

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

Read time: 1 mins
Last updated:2nd Jun 2021
Status: Completed
Identifier: NCT01810939

Brief Summary:
The purpose of this study was to evaluate the efficacy and safety of patiromer (investigational drug) in the treatment of hyperkalemia (high serum potassium). The study also evaluated the effect of withdrawing patiromer treatment and assessed whether chronic treatment with patiromer prevented the recurrence of hyperkalemia. The safety of patiromer treatment was also evaluated.

Detailed Description:
There were two parts in the study, Part A and Part B.

Part A was an assessment of 4 weeks of dosing with patiromer in the treatment of hyperkalemia; Part B was a randomized, placebo-controlled, 8-week assessment of the withdrawal of patiromer in participants with a baseline serum potassium at the beginning of Part A ≥ 5.5 mEq/L who responded to the 4 weeks of treatment with patiromer during Part A.

All participants received patiromer during Part A; Part B participants were randomized to continue patiromer or switch to placebo. Total study participation was up to 14 weeks (including up to 2 weeks of follow up).

The dose of patiromer could be titrated based on participant's serum potassium response.


Study Type: Interventional (Clinical Trial)
Actual Enrollment: 243 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia
Study Start Date: February 2013
Actual Primary Completion Date: July 2013
Actual Study Completion Date: August 2013

Arm:
- Active Comparator: Patiromer
- Placebo Comparator: Placebo

 

Category Value
Study type(s) Interventional
Expected enrolment 243
Study start date 2013-02-01
Estimated primary completion date 2013-07-01

View full details